Bevacizumab continuation versus no continuation after first-line chemo-bevacizumab therapy in patients with metastatic colorectal cancer: A randomized phase III noninferiority trial (SAKK 41/06).
Dieter Koeberle
Consultant or Advisory Role - Amgen; Bayer Schering Pharma; Merck Serono
Daniel C. Betticher
Consultant or Advisory Role - Lilly; Novartis; Pfizer; Roche; Sanofi
Roger Von Moos
Consultant or Advisory Role - Amgen; Merck Serono; MSD; Novartis; Roche
Honoraria - Amgen; Roche
Research Funding - Amgen; Roche
Expert Testimony - Roche (U); Sanofi (U)
Daniel Dietrich
No relevant relationships to disclose
Peter Brauchli
No relevant relationships to disclose
Daniela Baertschi
No relevant relationships to disclose
Klazien Matter-Walstra
No relevant relationships to disclose
Ralph C. Winterhalder
No relevant relationships to disclose
Markus M. Borner
No relevant relationships to disclose
Sandro Anchisi
Consultant or Advisory Role - Roche
Peter Moosmann
No relevant relationships to disclose
Attila Kollar
No relevant relationships to disclose
Piercarlo Saletti
No relevant relationships to disclose
Arnaud Roth
No relevant relationships to disclose
Martin Frueh
No relevant relationships to disclose
Marc Kueng
No relevant relationships to disclose
Razvan A. Popescu
Consultant or Advisory Role - Roche
Sabina Schacher
No relevant relationships to disclose
Viviane Hess
Consultant or Advisory Role - Roche
Research Funding - Roche (I)
Richard Herrmann
Consultant or Advisory Role - Roche